Clinical Trial: Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888088) titled 'Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults' on Oct. 15.

Brief Summary: Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial.

Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Epstein Barr Virus (EBV) Infection

Intervention: BIOLOGICAL: MVA-BN-EBV

MVA-BN-EBV

BIOLOGICAL: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bavarian Nordic

Published by HT Digital Con...